FindTrial
Sign In

LV5FU2

DRUG7 trials

Sponsors

Federation Francophone de Cancerologie Digestive, Gustave Roussy, Cancer Campus, Grand Paris, Centre Hospitalier Universitaire Dijon, Centre Hospitalier Universitaire de Besancon, Hopital Foch

Conditions

Adjuvant Chemotherapy for SBAColorectal CancerColorectal NeoplasmsMetastatic Colorectal CancerMetastatic Pancreatic CancerPancreas NeoplasmsPancreatic CancerSmall Bowel Adenocarcinoma

Phase 2

First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem
CompletedNCT02352337
Federation Francophone de Cancerologie DigestiveMetastatic Pancreatic Cancer
Start: 2015-01-12End: 2021-08-31Updated: 2024-07-10
Aflibercept +/- LV5FU2 in First Line of Non-resectalbe Metastatic Colorectal Cancers
CompletedNCT02384759
Federation Francophone de Cancerologie DigestiveColorectal Neoplasms
Start: 2015-05-31End: 2021-06-30Updated: 2024-07-10
Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases
CompletedNCT02494973
Gustave Roussy, Cancer Campus, Grand ParisColorectal Cancer
Start: 2015-05-26End: 2024-03-18Updated: 2024-10-28
Chemotherapy Intensification in Patients With High Lactate Dehydrogenase Values and Soluble Syndecan1 Levels
TerminatedNCT03117972
Centre Hospitalier Universitaire de BesanconMetastatic Colorectal Cancer
Start: 2017-08-04End: 2024-11-18Updated: 2025-02-05
Two Chemotherapy Regimens Plus or Minus Bevacizumab
Active, not recruitingNCT03351296
Gustave Roussy, Cancer Campus, Grand ParisPancreatic Cancer
Start: 2018-06-26End: 2028-12-31Updated: 2024-05-08
DOVIPA, a Study Evaluating Efficacy and Safety of DOstarlimab and VItamin D3 With mFOLFIRINOX in PAncreatic Cancer
RecruitingNCT06757244
Hopital FochPancreas Neoplasms
Start: 2025-02-18End: 2028-02-18Target: 35Updated: 2025-03-18

Phase 3

Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma
NCT02502370
Centre Hospitalier Universitaire DijonAdjuvant Chemotherapy for SBA, Small Bowel Adenocarcinoma
Target: 100Updated: 2015-07-20

Related Papers

Abstract 3654: Comparative efficacy of FOLFIRINOX versus gemcitabine plus nab-paclitaxel in metastatic pancreatic cancer: computing IPTW estimator while limiting patient data exposure with federated learning across 3 institutions
Cancer Research2025-04-21
Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer
The Oncologist2024-05-04
Postoperative hepatic arterial chemotherapy after resection of colorectal liver metastases in patients at high risk of hepatic recurrence: A multicenter randomized phase II trial (PRODIGE 43 - PACHA-01).
Journal of Clinical Oncology2023-06-019 citations
Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.
Journal of Clinical Oncology2019-05-203 citations
Randomized phase III trial of post-operative chemotherapy for patients with stage I/II/III small bowel adenocarcinoma (JCOG1502C, J-BALLAD)
Japanese Journal of Clinical Oncology2018-12-0721 citations
Exploratory analyses of 400 patients enrolled in 2 FFCD trials of first line treatment for metastatic pancreatic cancer
Annals of Oncology2018-10-011 citations
Postoperative hepatic arterial chemotherapy in high-risk patients as adjuvant treatment after resection of colorectal liver metastases - a randomized phase II/III trial - PACHA-01 (NCT02494973).
2018-08-0625 citations
FOLFIRINOX until progression, FOLFIRINOX with maintenance treatment, or sequential treatment with gemcitabine and FOLFIRI.3 for first-line treatment of metastatic pancreatic cancer: A randomized phase II trial (PRODIGE 35-PANOPTIMOX).
Journal of Clinical Oncology2018-05-2053 citations
Randomized phase III study of observation versus adjuvant capecitabine and oxaliplatin in curatively resected small bowel adenocarcinoma: A Japan Clinical Oncology Group study (JCOG1502C).
Journal of Clinical Oncology2018-02-012 citations